| Rheumatoid Arthritis
Vimovo vs Xeljanz
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Vimovo vs Xeljanz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXeljanz has a higher rate of injection site reactions vs Vimovo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xeljanz but not Vimovo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Vimovo
Xeljanz
At A Glance
Oral
Twice daily
NSAID + Proton Pump Inhibitor
Oral
Twice daily
JAK inhibitor
Indications
- Degenerative polyarthritis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Juvenile arthritis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Ulcerative Colitis
- Juvenile polyarthritis
Dosing
Degenerative polyarthritis, Rheumatoid Arthritis, Ankylosing spondylitis Adults: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily, taken orally at least 30 minutes before meals; use lowest effective naproxen dose for shortest duration.
Juvenile arthritis Adolescents >=12 years and >50 kg: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily; 38 kg to <50 kg: one tablet (375 mg naproxen/20 mg esomeprazole) twice daily, taken at least 30 minutes before meals.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis Adults: 5 mg twice daily (XELJANZ) or 11 mg once daily (XELJANZ XR).
Ulcerative Colitis Induction: 10 mg twice daily or 22 mg once daily for at least 8 weeks (up to 16 weeks); maintenance: 5 mg twice daily or 11 mg once daily.
Juvenile polyarthritis Weight-based dosing in pediatric patients >=2 years weighing >=10 kg; patients >=40 kg: 5 mg twice daily.
Contraindications
- Known hypersensitivity to naproxen, esomeprazole magnesium, substituted benzimidazoles, or any components of the drug product, including omeprazole
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Coronary artery bypass graft (CABG) surgery
- Concomitant use of rilpivirine-containing products
—
Adverse Reactions
Most common (>2%) Gastritis, diarrhea, upper respiratory tract infection, flatulence, headache, urinary tract infection, dysgeusia
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, DRESS, fetal toxicity, hematologic toxicity
Postmarketing Gait disturbance, abdominal distension, hematochezia, joint swelling, muscle spasms, renal tubular necrosis, angioedema, aplastic anemia, hepatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, hypomagnesemia, cutaneous lupus erythematosus
Most common (>=2%) Upper respiratory tract infection, nasopharyngitis, diarrhea, headache, hypertension.
Serious Serious infections (pneumonia, cellulitis, herpes zoster, urinary tract infection), malignancy, thrombosis, major adverse cardiovascular events, gastrointestinal perforations.
Postmarketing Drug hypersensitivity (angioedema, urticaria), acne.
Pharmacology
VIMOVO is a fixed-dose combination of naproxen, an NSAID that inhibits cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin synthesis with analgesic, anti-inflammatory, and antipyretic effects, and esomeprazole magnesium, a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase in the gastric parietal cell to reduce naproxen-associated gastric ulcer risk.
Tofacitinib is a JAK inhibitor that blocks JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 signaling, preventing phosphorylation and activation of STATs to modulate immune cell function and hematopoiesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vimovo
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (1/12)
Xeljanz
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Vimovo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Xeljanz
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Humana
Vimovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Xeljanz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Vimovo.
No savings programs available for Xeljanz.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VimovoView full Vimovo profile
XeljanzView full Xeljanz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.